Diversify Wealth Management LLC Sells 85,636 Shares of Grifols, S.A. $GRFS

Diversify Wealth Management LLC trimmed its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 77.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,509 shares of the biotechnology company’s stock after selling 85,636 shares during the period. Diversify Wealth Management LLC’s holdings in Grifols were worth $194,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. increased its stake in Grifols by 31.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 478,769 shares of the biotechnology company’s stock valued at $4,476,000 after acquiring an additional 113,539 shares during the period. SG Americas Securities LLC acquired a new position in Grifols in the fourth quarter worth about $1,048,000. Brandes Investment Partners LP lifted its stake in Grifols by 6.3% during the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after purchasing an additional 1,838,727 shares during the period. Norges Bank acquired a new stake in Grifols during the fourth quarter valued at approximately $18,139,000. Finally, BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of Grifols by 466.3% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 316,111 shares of the biotechnology company’s stock valued at $2,535,000 after purchasing an additional 260,295 shares during the period.

Grifols Price Performance

Shares of Grifols stock opened at $7.61 on Tuesday. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. The stock has a market capitalization of $5.18 billion, a price-to-earnings ratio of 40.05, a P/E/G ratio of 0.28 and a beta of 0.67. Grifols, S.A. has a 1-year low of $6.96 and a 1-year high of $11.14. The firm’s 50-day moving average price is $7.51 and its two-hundred day moving average price is $8.26.

Grifols Dividend Announcement

The firm also recently disclosed a special dividend, which was paid on Thursday, July 9th. Shareholders of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s payout ratio is currently 121.05%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Weiss Ratings cut Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered Grifols from a “buy” rating to a “hold” rating in a research note on Monday, May 18th. Three analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $10.00.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.